
Downloaded from: http://researchonline.lshtm.ac.uk/3750310/

DOI: 10.1016/j.jaad.2016.07.065

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Title: Psoriasis and Comorbid Diseases Part II. Implications for Management

Authors: Junko Takeshita, MD, PhD, MSCE1,2; Sungat Grewal, BS1; Sinéad M. Langan, MB, BCh, BAO, MRCP, MSc, PhD3; Nehal N. Mehta, MD, MSCE4; Alexis Ogdie, MD, MSCE2,5; Abby S. Van Voorhees, MD6; Joel M. Gelfand, MD, MSCE1,2.

Author Affiliations: Departments of Dermatology1, Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics2, and Division of Rheumatology5, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; London School of Hygiene and Tropical Medicine and St. John’s Institute of Dermatology, London, United Kingdom3; National Heart, Lung and Blood Institute, Bethesda, MD, USA4; Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA6.

Corresponding Author: Junko Takeshita, MD PhD MSCE, Department of Dermatology, University of Pennsylvania, 3400 Spruce St., 1104 Dulles, Philadelphia, PA 19104. Email: Junko.Takeshita@uphs.upenn.edu. Phone: 215-349-5551. Fax: 215-615-3127.

Funding/Support: This work was supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases K24AR064310 (Gelfand), T32AR007465-32 (Grewal), K23AR063764 (Ogdie), and K23AR068433 (Takeshita) grants, Dermatology Foundation Career Development Award (Takeshita), the Intramural Research Program at the National Institutes of Health, ZIAHL006193-02 (Mehta), and National Institute for Health Research Clinician Scientist
Fellowship, NIHR/CS/010/014 (Langan). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the U.K. Department of Health.

Conflict of Interest Disclosures: Dr. Takeshita receives a research grant (to the Trusteees of the University of Pennsylvania) from Pfizer and payment for continuing medical education work related to psoriasis. Dr. Mehta is a full time U.S. Government employee. Dr. Ogdie receives research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc. (to the Trustees of the University of Pennsylvania and GRAPPA), and has served as a consultant for Novartis, receiving honoraria. Dr. Van Voorhees has served as a consultant for AbbVie, Amgen, Aqua, AstraZeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria; received a research grant from AbbVie; and has other relationship with Merck. Dr. Gelfand has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.

Abstract word count: 94

Manuscript word count: 3473
Reference count: 99

Table count: 4

Figure count: 0